Israeli RNAi drug developer Silenseed this week published in vitro and in vivo data demonstrating the potential of its implantable siRNA delivery system to knock down the oncogene KRAS as a treatment for pancreatic cancer.

Meanwhile, as it nears the completion of a phase I trial of its RNAi drug delivery platform — called Local Delivery of RNAi, or LODER — Silenseed is preparing to begin a multinational phase II/III study that could lay the groundwork for US regulatory approval, a company official told Gene Silencing News.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.

Researchers report that what scents someone picks up can reflect their complement of immune genes.

The New York Times examines ethics and China's push to lead biomedical research.

At her blog, Sally Rockey dives into National Institutes of Health funding data.